Daunorubicin
- Generic Name
- Daunorubicin
- Brand Names
- Cerubidine, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO10
- CAS Number
- 20830-81-3
- Unique Ingredient Identifier
- ZS7284E0ZP
- Background
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.
- Indication
For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
Daunorubicin is indicated in combination with cytarabine for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Chronic Phase Chronic Myeloid Leukemia, Ewing's Sarcoma, Lymphoma, Diffuse, Myeloblastic Leukemia, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Wilms' tumor
Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
- Conditions
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Interventions
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2023-03-03
- Target Recruit Count
- 100
- Registration Number
- NCT05660473
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Conditions
- Myelodysplastic SyndromeAcute Myeloid Leukemia
- Interventions
- Procedure: Biospecimen CollectionOther: Best PracticeProcedure: Allogeneic Hematopoietic Stem Cell TransplantationProcedure: Bone Marrow AspirationProcedure: Biopsy ProcedureProcedure: Mutation Carrier ScreeningProcedure: Bone Marrow BiopsyProcedure: Echocardiography TestProcedure: Multigated Acquisition ScanDrug: Liposome-encapsulated Daunorubicin-CytarabineProcedure: Chest RadiographyProcedure: Computed TomographyProcedure: Positron Emission TomographyDrug: Placebo AdministrationRadiation: Total-Body Irradiation
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2000
- Registration Number
- NCT05564390
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Mercy Hospital South, Saint Louis, Missouri, United States
🇺🇸Siteman Cancer Center-South County, Saint Louis, Missouri, United States
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow Aspiration
- First Posted Date
- 2022-09-26
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 153
- Registration Number
- NCT05554393
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Banner University Medical Center - Tucson, Tucson, Arizona, United States
🇺🇸University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative NeoplasmAcute Myeloid Leukemia Post Cytotoxic TherapyAcute Myeloid LeukemiaAcute Myeloid Leukemia, Myelodysplasia-Related
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationDrug: Liposome-encapsulated Daunorubicin-CytarabineProcedure: Echocardiography TestProcedure: Multigated Acquisition Scan
- First Posted Date
- 2022-09-26
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 335
- Registration Number
- NCT05554406
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Banner University Medical Center - Tucson, Tucson, Arizona, United States
🇺🇸University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 200
- Registration Number
- NCT05453903
- Locations
- 🇪🇸
Hosp. de La Santa Creu I Sant Pau, Barcelona, Spain
🇪🇸Hosp Clinic de Barcelona, Barcelona, Spain
🇪🇸Hosp Univ Vall D Hebron, Barcelona, Spain
Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Ioannis Mantzaris
- Target Recruit Count
- 99
- Registration Number
- NCT05342584
- Locations
- 🇺🇸
Montefiore Einstein Cancer Center, Bronx, New York, United States
Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia
- Conditions
- B Acute Lymphoblastic LeukemiaPh-Like Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2021-12-15
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT05157971
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: Vyxeos、Daunorubicin Cytarabine liposome for injection
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2021-06-09
- Target Recruit Count
- 16
- Registration Number
- NCT04920500
- Locations
- 🇨🇳
Institute of Hematology and Hospital of Blood Disease, Chinese Academy of Medical Sciences, Tianjin, China
Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow Aspiration and Biopsy
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT04817241
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: Liposomal daunorubicin and cytarabine
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 172
- Registration Number
- NCT04801797
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of California - Davis, Sacramento, California, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.